Veru CEO to Present at Conference; Phase 2b PLATEAU Trial Starts Q1 2026
Veru CEO Mitchell Steiner will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26 from 3:20–3:50 pm ET via live webcast. The company reported positive Phase 2b QUALITY results for enobosarm with semaglutide and plans a 200-patient Phase 2b PLATEAU trial starting Q1 2026.
1. Conference Presentation
Mitchell Steiner, Veru CEO, will deliver a virtual presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26 from 3:20–3:50 pm ET, with live and archived webcasts available on the company website.
2. Enobosarm Phase 2b QUALITY Results
The Phase 2b QUALITY study enrolled 168 patients aged 60 and older receiving semaglutide, showing that enobosarm 3 mg and 6 mg preserved lean mass and physical function while augmenting fat loss over a 16-week active period versus placebo.
3. Upcoming Phase 2b PLATEAU Trial
Veru plans to initiate the Phase 2b PLATEAU trial in Q1 2026, enrolling approximately 200 patients aged 65 and older with BMI ≥ 35, to evaluate the impact of enobosarm 3 mg on body weight, composition, physical function, bone density, and safety over 68 weeks, with an interim readout at 34 weeks in Q1 2027.